学术报告一

题目：Cancer Theranostics

报告人：陈小元博士，新加坡国立大学医学院和工程学院终身讲席教授

时间：2023年5月18日 下午15：00

地点：霞光楼200号

邀请人：周永丰 教授

报告摘要：

Theranostics, the combination of ther(apy) and (diag)nostics, aims to develop molecular diagnostic tests and targeted therapeutics with the goals of individualizing treatment by targeting therapy to an individual's specific disease subtype and genetic profile. It can be diagnosis followed by therapy to stratify patients who will likely respond to a given treatment. It can also be therapy followed by diagnosis to monitor early response to treatment and predict treatment efficacy. It is also possible that diagnostics and therapeutics are co-developed (sonotheranostics, immunotheranostics, magnetotheranostics, optotheranostics, radiotheranostics, etc.). This talk will highlight two representative types of theranostics, namely radiotheranostics and immunotheranostics, in cancer imaging and therapy. Some translational work will also be mentioned.

学术报告二

题目：肿瘤原位纳米疫苗

报告人：邓宏章博士，西安电子科技大学教授

时间：2023年5月18日 下午16：00

地点：霞光楼200号

邀请人：周永丰 教授

报告摘要：

在所有威胁人类健康的疾病中，癌症无疑已经跃居榜首。传统治疗方式下肿瘤细胞凋亡之后的碎片可以作为抗原来激活肿瘤原位树突状细胞，进而引出免疫响应来实现肿瘤治疗。然后，由于肿瘤自身复杂的微环境以及保护机制，免疫性凋亡所产生的免疫响应比较微弱，并不能实现肿瘤治疗的目的。为此，结合先进纳米材料策略，以复杂肿瘤微环境为突破口来增强传统治疗方式所引发的免疫性凋亡是解决上述科学问题有效途径。构建多功能高分子原位纳米疫苗递送系统来重塑肿瘤细胞凋亡之后的抗原性与佐剂性，实现高效的肿瘤抑制。

学术报告三

题目：Lu-177/Ac-225-Based Radiotheranostics

报告人：张静静博士，新加坡国立大学

时间：2023年5月18日 下午16：30

地点：霞光楼200号

邀请人：周永丰 教授

报告摘要：

Radionuclide theranostics for precision oncology is being driven by rapid advances in novel diagnostics and therapeutic interventions, with dramatically expanded radiopharmaceuticals toolbox over the last few years. The rapid development and availability of new isotopes and agents has fundamentally changed the landscape for molecular targeted therapy. 177Lu-PRRT lends a significant benefit in progression free survival as well as in overall survival in metastasized and/or progressive NENs as compared to other treatment modalities and regardless of previous therapies. 177Lu-PSMA RLT is safe and effective with appropriate selection and follow-up of patients by 68Ga-PSMA PET/CT applying the concept of theranostics. The initial clinical results of PTRT provide preliminary evidence for the feasibility of radiomolecular precision theranostics using the novel FAP targeted radiolabeled ligands as well as TANDEM 177Lu-/225Ac- and 90Y-/225Ac-FAP of a number of advanced, therapy-refractory adenocarcinomas. Specific uptake and long tumor retention of the radioligands ensure usability of therapeutically effective longer-lived radionuclides for therapy. New strategies and platforms including new targets, novel radionuclides such as alpha emitter (225Ac, 212Pb), tumor microenvironment with optimized ligands and optimal isotopes (177Lu, 225Ac, 90Y, TANDEM) and administration schedules will be systematically explored in the near future.